ストックスクリーナーアプリを入手
4.26
0.70%
-0.03
プレマーケット:
4.25
-0.010
-0.23%
Ironwood Pharmaceuticals Inc (IRWD) 最新ニュース
IRWD stock gains as Wells Fargo conference spotlight shifts to cash flow - AD HOC NEWS
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Ironwood Pharmaceuticals (IRWD) Slips 2.6% as Shares Approach Key Support at $3.92Backspread Trade - vinanet.vn
Ironwood Pharmaceuticals Inc. Class A (IRWD) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Ironwood Pharmaceuticals: High Dependence On Its Next Trial (NASDAQ:IRWD) - Seeking Alpha
Ironwood (IRWD) Results Versus Estimates: EPS Does Not Reach the Reported Estimate for the Current Session; Market Move: The Market Price Moves 1.16% Higher in Latest TradingEarnings Yield Analysis - vinanet.vn
Ironwood Pharmaceuticals (IRWD) Edges Higher: Shares Advance 1.16% as Bulls Defend Key SupportRSI Oversold Picks - vinanet.vn
Jeffrey Silber Net Worth (2026) - GuruFocus
Bank of America Corp DE Sells 2,838,753 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo
Ironwood Pharmaceuticals (IRWD) Q2 2026 Earnings: EPS Misses Estimates, Stock Climbs 5.64%Dividend Growth Analysis - vinanet.vn
Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake - Stock Titan
Dimensional Fund Advisors LP Raises Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownTime to Sell? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Amundi - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
State Street Corporation (NYSE: IRWD caretaker) holds 5.4% of Ironwood common stock - Stock Titan
Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pacer Advisors Inc. Makes New $3.98 Million Investment in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call High - GuruFocus
Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed? - Yahoo! Finance Canada
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ... - Yahoo Finance
IRWD Looks 15.8% Undervalued on GF Value™ as Debt Reduction Effo - GuruFocus
Ironwood Pharmaceuticals Q2 Earnings Call Highlights - Yahoo Finance
Ironwood Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-08-06 - Seeking Alpha
Is Ironwood Pharmaceuticals (IRWD) Undervalued After Q2 Earnings - GuruFocus
IRWD: LINZESS sales surged and guidance was raised as apraglutide advanced in phase III trials - TradingView
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates - Yahoo Finance
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Ironwood Raises 2026 Guidance After Q2 Revenue Hits $113 Million - Quiver Quantitative
BRIEF-Ironwood Pharmaceuticals Q2 Revenue USD 113.041 Million Vs. IBES Estimate USD 114.8 Million - TradingView
Press Release: Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results - Moomoo
Segall Bryant & Hamill LLC Buys New Position in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Lazard Asset Management LLC Sells 710,256 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (IRWD) Advances 2.89% to $4.27 — Key Resistance at $4.48 in FocusRevenue Growth Stocks - vinanet.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to "Hold" at Zacks Research - MarketBeat
Ironwood Pharmaceuticals (IRWD) Surges 13% as Biotech Momentum BuildsLow Vol Factor - vinanet.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 8.7%Should You Buy? - MarketBeat
Ironwood Pharmaceuticals Q1 2026 Earnings: Slight EPS Miss Overshadowed by Positive Stock MomentumEPS Revision Trend - vinanet.vn
Ironwood Pharmaceuticals Inc (IRWD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BlackRock, Inc. (NASDAQ: IRWD) discloses 8.1% beneficial stake in Ironwood - Stock Titan
Ironwood Pharmaceuticals Inc (IRWD) Institutional Confidence - TradingKey
Return on assets % of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76 - TradingView
Total operating expenses of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76 - TradingView
Ironwood Pharmaceuticals Inc (IRWD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AbbVie Seeks Block On Alkem Generic Constipation Drug - Law360
Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – BX:I76 - TradingView
Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – SWB:I76 - TradingView
Ironwood Pharmaceuticals Inc (IRWD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IRWD|Ironwood Pharmaceuticals Inc|Price:4.265|Chg%:-0.025 - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IRWD|Ironwood Pharmaceuticals Inc|Price:3.710|Chg%:-0.080 - TradingKey
Ironwood Pharmaceuticals Inc (I76.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
IRWD: Ironwood Pharmaceuticals IncOrdinary SharesClass A Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Globeflex Capital L P Purchases New Shares in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (IRWD) grants 137,036-share RSU new-hire award to CMO - Stock Titan
Ironwood Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- Silber Jeffrey - Moomoo
Ironwood Pharmaceuticals (IRWD) Jefferies 2024 Global Healthcare Conference Summary - Quartr
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating - Moomoo
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development, STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients - marketscreener.com
Here's why Ironwood Pharmaceuticals (IRWD) is a strong momentum stock - MSN
Ironwood’s 30-year medical chief retires as Phase 3 trial recruits - Stock Titan
Ironwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The Gap (NASDAQ:IRWD) - Seeking Alpha
Ironwood Pharmaceuticals (NASDAQ: IRON) plans 33,000-share sale via options exercise - Stock Titan
Insider Sell Alert: Ronald Silver Sells Shares of Ironwood Pharm - GuruFocus
Form 4 Ironwood Pharmaceuticals Inc For: 9 July - Investing.com India
1.66%
0.33%
大文字化:
|
ボリューム (24 時間):